The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum anti-infective that has the potential to treat multi-drug resistant Pseudomonas and other infections in people with cystic fibrosis.
Site Search
Showing 11 - 20 of 41 results
Press Release
|
July 15, 2021
|
2 min read
Press Release
|
Jan. 26, 2021
|
3 min read
Lee University